Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Falchi

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Blood Advances|June 11, 2024
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomasGustav Y Cederquist, Javin Schefflein, Sean M Devlin, et al.
Hemasphere|December 1, 2025
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphomaEfrat Luttwak, David Nemirovsky, Sean M Devlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven ApproachLindsey E Roeker, Tatyana A Feldman, Jacob D Soumerai, et al.
Blood Cancer Journal|July 18, 2020
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Blood|October 22, 2024
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutationAnita Kumar, Jacob Soumerai, Jeremy S Abramson, et al.
Blood Advances|June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamabAllison M Bock, Lei Feng, Ayushi Chauhan, et al.
Lancet (London, England)|December 10, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trialLorenzo Falchi, Marcel Nijland, Huiqiang Huang, et al.
Blood Advances|August 15, 2025
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaXavier Deschênes-Simard, Maria Bromberg, Sean M Devlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2026
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell LymphomaManik Uppal, Bhavneet Bhinder, Andrew R Marderstein, et al.
Blood Cancer Journal|February 11, 2022
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphomaFushen Sha, Michelle Okwali, Anna Alperovich, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Blood Advances|June 11, 2024
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomasGustav Y Cederquist, Javin Schefflein, Sean M Devlin, et al.
Hemasphere|December 1, 2025
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphomaEfrat Luttwak, David Nemirovsky, Sean M Devlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven ApproachLindsey E Roeker, Tatyana A Feldman, Jacob D Soumerai, et al.
Blood Cancer Journal|July 18, 2020
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Blood|October 22, 2024
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutationAnita Kumar, Jacob Soumerai, Jeremy S Abramson, et al.
Blood Advances|June 9, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamabAllison M Bock, Lei Feng, Ayushi Chauhan, et al.
Lancet (London, England)|December 10, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trialLorenzo Falchi, Marcel Nijland, Huiqiang Huang, et al.
Blood Advances|August 15, 2025
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaXavier Deschênes-Simard, Maria Bromberg, Sean M Devlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2026
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell LymphomaManik Uppal, Bhavneet Bhinder, Andrew R Marderstein, et al.
Blood Cancer Journal|February 11, 2022
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphomaFushen Sha, Michelle Okwali, Anna Alperovich, et al.
Pageof 8